Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-cash Items (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Non-cash Items for 11 consecutive years, with $502733.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items rose 477.85% to $502733.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $502733.0 through Dec 2025, up 477.85% year-over-year, with the annual reading at $502733.0 for FY2025, 477.85% up from the prior year.
  • Non-cash Items hit $502733.0 in Q4 2025 for Seres Therapeutics, down from $2.3 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $854.1 million in Q2 2022 to a low of $87000.0 in Q4 2024.
  • Historically, Non-cash Items has averaged $64.7 million across 5 years, with a median of $7.1 million in 2022.
  • Biggest five-year swings in Non-cash Items: tumbled 99.2% in 2023 and later soared 7356.56% in 2024.
  • Year by year, Non-cash Items stood at $28.0 million in 2021, then tumbled by 58.55% to $11.6 million in 2022, then crashed by 59.26% to $4.7 million in 2023, then tumbled by 98.16% to $87000.0 in 2024, then skyrocketed by 477.85% to $502733.0 in 2025.
  • Business Quant data shows Non-cash Items for MCRB at $502733.0 in Q4 2025, $2.3 million in Q3 2025, and $499042.0 in Q2 2025.